Hemodialysis treatment includes hemodialysis, hemofiltration, hemoperfusion, plasma exchange, immunoadsorption and continuous renal replacement therapy.
Second, the hemodialysis market analysis
Globally, hemodialysis has been and will continue to be the main treatment for patients with chronic kidney disease. In recent years, the global dialysis market has steadily increased from 66.8 billion euros in 20 15 to 82 billion euros in 2020, with an average annual growth rate of about 4%. By 202 1, the dialysis market will continue to grow to 83 billion to 85 billion euros. Among them, the market scale of dialysis services (including drugs) accounts for more than 80%.
In China, hemodialysis is the most commonly used treatment option for patients with ESRD, and it has great growth potential. According to the clinical practice guideline of hemodialysis adequacy in China, most ESRD patients in China received hemodialysis 2-3 times a week, and in 20021year, 8.8765438 billion people in China received blood purification treatment, including 6.5438+0.3 billion people with peritoneal dialysis and 7.57 billion people with hemodialysis.
Hemodialysis in China is mainly carried out in independent hemodialysis centers operated by nephrology departments and hospitals, while hemodialysis in the United States is mainly carried out in independent hemodialysis centers. Although the number of hospitals and dialysis centers per million people in China will increase to 6,377 or 4.5 in 2020, which is partly due to the promulgation of supporting policies since 2065, the number of hospitals and dialysis centers per million people is still far lower than that in the United States, and there is still a big gap in the demand for hemodialysis in China.
According to the epidemiological survey of chronic kidney disease in China, the incidence of adult chronic kidney disease in China is as high as 10.8%, that is, about1500,000 people have different degrees of renal function damage. According to the proportion that about 1.5% of patients with chronic kidney disease will develop into end-stage kidney disease in the United States, among them, there are about 2 million patients with end-stage kidney disease, of which only 340,000 patients receive dialysis treatment, accounting for only.
According to statistics, during 20 19-202 1, China * * * collected 4,270 items of bidding data for hemodialysis equipment, involving 60 brands, with a total purchase amount of 7.85 billion yuan; The bidding market scale of hemodialysis equipment has rapidly increased from165438+59 million yuan to 3.697 billion yuan.
Third, the development prospect of hemodialysis
According to the annual growth rate of 7% of patients with end-stage renal disease in Fei Sen, by 2020, there will be 3.2 million patients with end-stage renal disease in China; Assuming that after five years, the domestic dialysis treatment rate reaches the current world average of 37%, and the average treatment cost remains unchanged (70,000/year), the future hemodialysis market will reach 75 billion (accounting for 90%).
Since 20 12 the State Council included uremia in the medical insurance for serious illness, the medical insurance payment policy for serious illness has been further implemented, covering urban and rural residents. The specific medical insurance payment policy varies from region to region: in some regions, hemodialysis expenses are packaged and charged, and medical insurance directly reimburses 90%, and pays10%; In some areas, the new rural cooperative medical system and the civil affairs bureau share 90% of the costs; In other areas, consumables are reimbursed separately from treatment fees and medicines, and the reimbursement ratio is different, but the overall reimbursement ratio can also reach 80%.
In recent years, with the development of economy, the improvement of quality of life and the arrival of aging population, the incidence of chronic diseases such as hypertension and diabetes has gradually increased, and the proportion of patients with end-stage renal disease caused by it has increased year by year. According to the latest epidemiological data, chronic kidney disease has become one of the main diseases that threaten people's health. At present, there are about10.2 billion patients in China, and the prevalence rate is as high as 10.8%. Among them, there are more than 3 million uremia patients, and the number of new patients is10-150,000 every year, which means that the base of patients with end-stage renal disease in China is very large and growing rapidly. The demand for hemodialysis is increasing. According to relevant data, by 2020, the number of hemodialysis patients in China has reached 692,736, and the number of hemodialysis patients in that year was 1435 13, and the total prevalence rate of hemodialysis was 494.9pmp.
Some provinces in China have successively issued policies to encourage the construction of independent hemodialysis centers, and the dialysis service of social capital development will enter a golden age. According to the current situation of 75,000 yuan annual treatment cost, the hemodialysis market in China has reached 39.3 billion yuan, and reached 46.73 billion yuan in 20 18. With the increase of the proportion of dialysis patients and the number of ESRD patients, it is estimated that the dialysis market will exceed130 billion yuan by 2025, with an annual growth rate of 16%.